Key result
Cardiac biomarkers remain the strongest predictors of survival in AL amyloidosis, with novel markers improving risk models.
Why the study?
Existing prognostic models for systemic AL amyloidosis rely on cardiac biomarkers with low specificity and dependence on confounders, while new therapies and advancing imaging and biological markers are emerging.
Continuous reevaluation of prognostic markers in systemic AL amyloidosis is required to optimize patient management in the modern era of targeted anti-plasma cell therapies.
Answers are grounded in this paper and cite their sources.
Cardiac biomarkers guide prognosis in systemic AL amyloidosis; leaves open whether sST2, GDF-15, or imaging enhance modern models without prospective validation.
INTRODUCTION: Systemic AL amyloidosis (ALA) is a clonal plasma cell (PC) disease characterized by deposition of amyloid fibrils in different organs and tissues. Traditionally, the prognosis of ALA is poor and is primarily defined by cardiac involvement. The modern prognostic models are based on cardiac markers and free light chain difference (dFLC). Cardiac biomarkers have low specificity and are dependent on renal function, volume status, and cardiac diseases other than ALA. New therapies significantly improved the prognosis of the disease. The advancements in technologies - cardiac echocardiography (ECHO) and cardiac MRI (CMR), as well as new biological markers, relying on cardiac injury, inflammation, endothelial damage, and clonal and non-clonal PC markers are promising. AREAS COVERED: An update on the prognostic significance of cardiac ALA, number of involved organs, response to treatment, including minimal residual disease (MRD), ECHO, MRI, and new biological markers will be discussed. The literature search was done in PubMed and Google Scholar, and the most recent and relevant data are included. EXPERT OPINION: Prospective multicenter trials, evaluating multiple clinical and laboratory parameters, should be done to improve the risk assessment models in ALA in the modern era of therapy.
No takes yet. Share an insight, caveat, or question.
Kreiniz et al. (2023) conducted a review in Systemic AL amyloidosis. Prognostic biomarkers and imaging (e.g., cardiac markers, ECHO, CMR, novel biomarkers) was evaluated. Cardiac biomarkers remain the strongest predictors of survival in systemic AL amyloidosis, while emerging markers like sST2, GDF-15, and advanced imaging parameters hold promise for improving modern risk assessment models.
Synapse has enriched 10 related papers. Consider them for comparative context: